Biomarkers /

GPS2

Back to Biomarkers List

Overview

Location [1]
17p13.1
Protein [2]
G protein pathway suppressor 2
Synonyms [1]
AMF-1

GPS2 is altered in 0.73% of all cancers with breast invasive ductal carcinoma, prostate adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].

GPS2 GENIE Cases - Top Diseases

The most common alterations in GPS2 are GPS2 Mutation (0.43%), GPS2 Loss (0.30%), GPS2 Amplification (0.04%), GPS2 E74del (0.03%), and GPS2 X133_splice (0.02%) [3].

GPS2 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.